GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Days Sales Outstanding
中文

Daiichinkyo Co (Daiichinkyo Co) Days Sales Outstanding : 87.76 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Days Sales Outstanding?

Daiichinkyo Co's average Accounts Receivable for the three months ended in Dec. 2023 was $2,985 Mil. Daiichinkyo Co's Revenue for the three months ended in Dec. 2023 was $3,104 Mil. Hence, Daiichinkyo Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 87.76.

The historical rank and industry rank for Daiichinkyo Co's Days Sales Outstanding or its related term are showing as below:

DSKYF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 87.1   Med: 96.61   Max: 135.5
Current: 95.43

During the past 13 years, Daiichinkyo Co's highest Days Sales Outstanding was 135.50. The lowest was 87.10. And the median was 96.61.

DSKYF's Days Sales Outstanding is ranked worse than
71.1% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs DSKYF: 95.43

Daiichinkyo Co's Days Sales Outstanding declined from Dec. 2022 (89.70) to Dec. 2023 (87.76).

Daiichinkyo Co Days Sales Outstanding Historical Data

The historical data trend for Daiichinkyo Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Days Sales Outstanding Chart

Daiichinkyo Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.00 133.06 103.22 90.79 92.75

Daiichinkyo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.70 96.88 98.80 99.66 87.76

Competitive Comparison of Daiichinkyo Co's Days Sales Outstanding

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Days Sales Outstanding falls into.


Daiichinkyo Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Daiichinkyo Co's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

Days Sales Outstanding (A: Mar. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )*Days in Period
=( (2248.953 + 2611.849) / 2 ) / 9564.843*365
=2430.401 / 9564.843*365
=92.75

Daiichinkyo Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2785.16 + 3185.298) / 2 ) / 3104.045*365 / 4
=2985.229 / 3104.045*365 / 4
=87.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co  (OTCPK:DSKYF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Daiichinkyo Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Days Sales Outstanding
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSNKY:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.